Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:
A Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 673-676, 2021.
Article
em Zh
| WPRIM
| ID: wpr-922240
Biblioteca responsável:
WPRO
ABSTRACT
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Piperidinas
/
Neoplasias Pleurais
/
Carbazóis
/
Tomografia Computadorizada por Raios X
/
Estudos Retrospectivos
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Quinase do Linfoma Anaplásico
/
Neoplasias Pulmonares
/
Mutação
Tipo de estudo:
Observational_studies
/
Screening_studies
Limite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2021
Tipo de documento:
Article